# T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

> **NCT03530696** · PHASE2 · COMPLETED · sponsor: **University of Arizona** · enrollment: 55 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Breast Cancer
- Breast Cancer Stage
- Recurrent Breast Cancer
- Metastatic Breast Cancer
- HER2 Positive Breast Carcinoma

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT03530696
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2022-12-22
- **Final completion:** 2022-12-22
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03530696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03530696, "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03530696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*